key: cord-0743777-2k75d3u7 authors: Iannone, Michela; Janowska, Agata; Tonini, Giulia; Davini, Giulia; Dini, Valentina title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa date: 2021-05-19 journal: Clin Dermatol DOI: 10.1016/j.clindermatol.2021.05.026 sha: 37f0732f9c72719a19f94085e8f2c21dc0f1e203 doc_id: 743777 cord_uid: 2k75d3u7 nan To the editor: The COVID-19 pandemic spreading had a major impact on our daily lives imposing worldwide healthcare providers to modify their methods of clinical practice. The COVID-19 vaccination is urgently needed to control the epidemic and return to normal life 1 . To date, three different types of vaccines have been approved in Italy: two based on spike protein mRNA carried by lipidic microparticles and one based on spike protein mRNA carried by adenoviruses. The technology of these vaccines is different; this, combined with short development times and new technologies adopted, makes it necessary to collect real life efficacy and safety data 2 . Hidradenitis suppurativa (HS) is a chronic relapsing skin inflammatory disease. The therapeutic management of HS is based on immunosuppressive therapies (steroids, dapsone, cyclosporine) or immunomodulatory therapies (antibiotics or biological drugs) 3 Although larger population studies are needed to validate safety and efficacy of mRNA vaccines during biological treatment, our case confirms that the vaccine administration in HS patient treated with anti-IL-17 drugs is safe and effective. The patient developed hightitled antibody response, despite the important role of Th17 axis in natural infection clearance and in the development of vaccine-induced immunity 5 . COVID-19 Vaccine and Biologics: An Impending Dilemma COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead Systemic antibiotics in hidradenitis suppurativa: efficacy and effects of body mass index and smoking pack-year on the response to therapy Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic Immunological mechanisms of vaccination